Sarepta Therapeutics has ushered in a new chapter in the treatment of Duchenne Muscular Dystrophy (DMD) with the introduction of ELEVIDYS (delandistrogene moxeparvovec-rokl), the first gene therapy approved for this devastating disorder. With the U.S. Food and Drug Administration (FDA) granting accelerated approval in June 2023, ELEVIDYS offers hope by addressing the root cause of DMD....
Duchenne muscular dystrophy (DMD) is a severe genetic disorder characterized by progressive muscle degeneration, primarily affecting boys. While a definitive cure remains elusive, groundbreaking innovations in research and treatment are breaking barriers and providing new hope for patients and their families. This article highlights some of the most promising approaches currently being...
Duchenne muscular dystrophy (DMD) is a severe genetic disorder characterized by progressive muscle degeneration, primarily affecting young boys. The market for DMD therapeutics has made significant strides in recent years, particularly with the advent of exon-skipping therapies. However, the quest to improve patient outcomes has driven researchers and pharmaceutical companies to explore...
Gene therapy has emerged as a revolutionary approach to treating genetic disorders, offering potential cures where traditional therapies may only provide symptomatic relief. However, the high costs associated with these therapies have sparked significant debate regarding their pricing and reimbursement strategies. This article examines the economic implications of gene therapy, exploring the...
Neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), Spinal Muscular Atrophy (SMA), and Amyotrophic Lateral Sclerosis (ALS), involve progressive muscle degeneration and neurological impairments, posing immense challenges for patients and caregivers. However, antisense oligonucleotides (ASOs) and small interfering RNA (siRNA) therapies offer promising solutions by targeting...
Duchenne Muscular Dystrophy (DMD) is a severe genetic disorder caused by mutations in the dystrophin gene, resulting in progressive muscle degeneration. Typically diagnosed in early childhood, the condition leads to the loss of ambulation by adolescence and, without intervention, premature death due to respiratory or cardiac complications. However, recent breakthroughs in medical research and...
Duchenne Muscular Dystrophy (DMD) is a severe genetic disorder characterized by progressive muscle degeneration and weakness, primarily affecting boys. Caused by mutations in the dystrophin gene, DMD leads to the absence of dystrophin, a vital protein for muscle health. Historically, DMD has posed significant challenges for both patients and researchers, with limited treatment options focused...
English
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian